Organon and Medarex announce antibody development agreement

03-Feb-2006

Organon and Medarex, Inc. announced an agreement for the development of therapeutic antibodies. Organon intends to use Medarex's UltiMAb Human Antibody Development System®, which allows for the discovery of fully human antibodies in mice, to generate therapeutic antibodies against a variety of disease targets discovered by Organon and/or its alliance partners in discovery research. Financial terms were not disclosed.

Under the terms of the agreement, Organon plans to develop and commercialize fully human antibody therapeutics. Medarex expects to receive license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous